Apollo Health Webinar Shares Breakthrough Alzheimer’s Trial Results Part 1

In a recent Apollo Health webinar, founder and Chief Scientific Officer Dale Bredesen joined clinical investigators Dr. Ann Hathaway and Dr. Kat Toups to present results from a newly completed randomized controlled trial evaluating a precision medicine approach using the ReCODE program to address mild cognitive impairment and early Alzheimer’s disease.

The nine-month, multi-site study compared personalized, root-cause-based treatment to standard of care and revealed a striking divergence in outcomes: participants receiving the precision medicine protocol showed statistically significant improvements in memory, executive function, processing speed, and overall cognition, while those receiving standard care continued to decline.

Watch here: